 | Up a level |
Afferi, Luca; Spahn, Martin; Hayoz, Stefanie; Strebel, Räto T; Rothschild, Sacha I; Seifert, Helge; Özdemir, Berna C; Kiss, Bernhard; Maletzki, Philipp; Engeler, Daniel; Wirth, Gregory; Hadaschik, Boris; Lucca, Ilaria; John, Hubert; Sauer, Andreas; Müntener, Michael; Bubendorf, Lukas; Schneider, Martina; Musilova, Jana; Petrausch, Ulf; ... (2024). Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine. BJU international, 134(3), pp. 388-397. Wiley 10.1111/bju.16318
Özdemir, Berna C (2024). Removing barriers to address sex differences in anticancer drug toxicity. Nature reviews - cancer, 24(3), pp. 161-162. Nature Publishing Group 10.1038/s41568-023-00651-w
Darphin, Xenia; Moor, Jeanne; da Silva, Cristina Espinosa; Richters, Anke; Özdemir, Berna C (2024). Awareness of the impact of sex and gender in the disease risk and outcomes in hematology and medical oncology-a survey of Swiss clinicians. Cancer reports, 7(2), e1961. Wiley 10.1002/cnr2.1961
Richters, Anke; Robbrecht, Debbie G J; Meijer, Richard P; van der Heijden, Antoine G; Kiemeney, Lambertus A L M; van den Bosch, Joan; Suelmann, Britt B M; Özdemir, Berna C; Mehra, Niven; Aben, Katja K H (2024). Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort. European urology open science, 59, pp. 50-54. Elsevier 10.1016/j.euros.2023.11.010
Bührer, Elias D; Alberts, Ian L; Christ, Lisa; Özdemir, Berna C (2024). Successful treatment of immune checkpoint inhibitor-related periaortitis. Swiss medical weekly, 154(2) SMW supporting association 10.57187/s.3631
Benzaquen, M; Christ, L; Sutter, N; Özdemir, B C (2023). Nivolumab-induced eosinophilic fasciitis: An unusual immune-related adverse event that needs to be recognized by practitioners. Annales de dermatologie et de vénéréologie, 150(4), pp. 304-307. Elsevier 10.1016/j.annder.2023.07.001
Cathomas, Richard; Rothschild, Sacha I; Hayoz, Stefanie; Bubendorf, Lukas; Özdemir, Berna C; Kiss, Bernhard; Erdmann, Andreas; Aeppli, Stefanie; Mach, Nicolas; Strebel, Räto T; Hadaschik, Boris; Berthold, Dominik; John, Hubert; Zihler, Deborah; Schmid, Mathias; Alborelli, Ilaria; Schneider, Martina; Musilova, Jana; Spahn, Martin and Petrausch, Ulf (2023). Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. Journal of clinical oncology, 41(33), pp. 5131-5139. American Society of Clinical Oncology 10.1200/JCO.23.00363
Tran, Linh Chi; Özdemir, Berna C; Berger, Martin D (2023). The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook. Pharmaceuticals, 16(10) MDPI 10.3390/ph16101411
Liu, Michael; Christ, Lisa; Richters, Anke; Özdemir, Berna C (2023). Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease. Oncology letters, 26(3), p. 377. Spandidos Publications 10.3892/ol.2023.13963
Wahli, Murielle N; Hayoz, Stefanie; Hoch, Dennis; Ryser, Christoph O; Hoffmann, Michèle; Scherz, Amina; Schwacha-Eipper, Birgit; Häfliger, Simon; Wampfler, Julian; Berger, Martin D; Novak, Urban; Özdemir, Berna C (2023). The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex. Journal of cancer research and clinical oncology, 149(7), pp. 3847-3858. Springer 10.1007/s00432-022-04309-2
Özdemir, Berna C; Espinosa da Silva, Cristina; Arangalage, Dimitri; Monney, Pierre; Guler, Sabina A; Huynh-Do, Uyen; Stirnimann, Guido; Possamai, Lucia; Trepp, Roman; Hoepner, Robert; Salmen, Anke; Gerard, Camille L; Hruz, Petr; Christ, Lisa; Rothschild, Sacha I (2023). Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients. Cancer immunology, immunotherapy : CII, 72(7), pp. 1991-2001. Springer 10.1007/s00262-023-03436-0
Özdemir, Berna C; Espinosa da Silva, Cristina; Arangalage, Dimitri; Monney, Pierre; Guler, Sabina A; Huynh-Do, Uyen; Stirnimann, Guido; Possamai, Lucia; Trepp, Roman; Hoepner, Robert; Salmen, Anke; Gerard, Camille L; Hruz, Petr; Christ, Lisa; Rothschild, Sacha I (2023). Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients. Cancer immunology, immunotherapy : CII, 72(7), pp. 2003-2004. Springer 10.1007/s00262-023-03456-w
Özdemir, Berna C; Richters, Anke; Espinosa da Silva, Cristina; Berner, Alison May (2023). Cancer researchers' perceptions of the importance of the sex of cell lines, animals, and human samples for cancer biology research. iScience, 26(4), p. 106212. Elsevier 10.1016/j.isci.2023.106212
Özdemir, Berna C; Arnold, Nicolas; Fleischmann, Achim; Hensel, Janine; Klima, Irena; Kruithof-de Julio, Marianna; Burkhard, Fiona; Hayoz, Stefanie; Kiss, Bernhard; Thalmann, George N (2022). Prediction of Biochemical Recurrence Based on Molecular Detection of Lymph Node Metastasis After Radical Prostatectomy. European urology open science, 44, pp. 1-10. Elsevier 10.1016/j.euros.2022.07.005
Richters, Anke; Leliveld, Anna M; Goossens-Laan, Catharina A; Aben, Katja K H; Özdemir, Berna C (2022). Sex differences in treatment patterns for non-advanced muscle-invasive bladder cancer: a descriptive analysis of 3484 patients of the Netherlands Cancer Registry. World journal of urology, 40(9), pp. 2275-2281. Springer 10.1007/s00345-022-04080-6
Özdemir, Berna C; Wagner, Anna Dorothea (2022). Consideration of sex and gender aspects in oncology: rationale, current status, and perspectives. The Italian gender-specific medicine, 8(1), pp. 55-58. Il Pensiero Scientifico Editore 10.1723/3769.37567
Özdemir, Berna C; Gerard, Camille L; Espinosa da Silva, Cristina (2022). Sex and gender differences in anticancer treatment toxicity - a call for revisiting drug dosing in oncology. Endocrinology, 163(6) Endocrine Society 10.1210/endocr/bqac058
Hoffmann, Michèle; Hayoz, Stefanie; Özdemir, Berna C. (2022). Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma-A Real World Single-Center Analysis. Biology, 11(3) MDPI 10.3390/biology11030422
Özdemir, B C; Oertelt-Prigione, S; Adjei, A A; Borchmann, S; Haanen, J B; Letsch, A; Mir, O; Quaas, A; Verhoeven, R H A; Wagner, A D (2022). Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force. Annals of oncology, 33(2), pp. 126-128. Elsevier 10.1016/j.annonc.2021.11.011
Hoffmann, Michèle; Schardt, Julian; Ionescu, Codruta; Wolf-Schnurrbusch, Ute E.; Wagner, Franca; Dettmer, Matthias S.; Olariu, Radu; Özdemir, Berna C. (2021). Long lasting response to anti-PD-1 therapy of recurrent conjunctival squamous cell carcinoma - A case report and systematic review of the literature. Current problems in cancer: case reports, 4, p. 100088. Elsevier 10.1016/j.cpccr.2021.100088
Arangalage, Dimitri; Degrauwe, Nils; Michielin, Olivier; Monney, Pierre; Özdemir, Berna C. (2021). Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Cancer treatment reviews, 100, p. 102282. Elsevier 10.1016/j.ctrv.2021.102282
Arangalage, Dimitri; Pavon, Anna Giulia; Özdemir, Berna C; Michielin, Olivier; Schwitter, Jurg; Monney, Pierre (2021). Acute cardiac manifestations under immune checkpoint inhibitors-beware of the obvious: a case report. European heart journal - case reports, 5(8), ytab262. Oxford University Press 10.1093/ehjcr/ytab262
Ghisoni, E; Wicky, A; Bouchaab, H; Imbimbo, M; Delyon, J; Gautron Moura, B; Gérard, C L; Latifyan, S; Özdemir, B.C.; Caikovski, M; Pradervand, S; Tavazzi, E; Gatta, R; Marandino, L; Valabrega, G; Aglietta, M; Obeid, M; Homicsko, K; Mederos Alfonso, N N; Zimmermann, S; ... (2021). Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. European journal of cancer, 149, pp. 153-164. Elsevier 10.1016/j.ejca.2021.03.010
Ma, Min; Ghosh, Soumitra; Tavernari, Daniele; Katarkar, Atul; Clocchiatti, Andrea; Mazzeo, Luigi; Samarkina, Anastasia; Epiney, Justine; Yu, Yi-Ru; Ho, Ping-Chih; Levesque, Mitchell P; Özdemir, Berna C.; Ciriello, Giovanni; Dummer, Reinhard; Dotto, G Paolo (2021). Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. The Journal of experimental medicine, 218(2) Rockefeller Univ. Press 10.1084/jem.20201137
Özdemir, Berna C (2021). Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology. Journal for immunotherapy of cancer, 9(2) BMJ Publishing Group 10.1136/jitc-2020-002220
Özdemir, Berna C. (2021). Androgen Signaling in the Tumor Microenvironment. In: Tumor Microenvironment, Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology: Vol. 1270 (pp. 169-183). Springer 10.1007/978-3-030-47189-7_10
Oezdemir, Berna; Hensel, Janine; Secondini, Chiara; Wetterwald, Antoinette; Schwaninger, Ruth; Fleischmann, Achim; Raffelsberger, Wolfgang; Poch, Olivier; Delorenzi, Mauro; Temanni, Ramzi; Mills, Ian G; van der Pluijm, Gabri; Thalmann, George; Cecchini, Marco Giovanni (2014). The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches. PLoS ONE, 9(12), e114530. Public Library of Science 10.1371/journal.pone.0114530
